XBiotech Statistics
Total Valuation
XBiotech has a market cap or net worth of $92.68 million. The enterprise value is -$63.21 million.
Important Dates
The next estimated earnings date is Tuesday, May 27, 2025, after market close.
| Earnings Date | May 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XBiotech has 30.49 million shares outstanding. The number of shares has increased by 0.07% in one year.
| Current Share Class | 30.49M |
| Shares Outstanding | 30.49M |
| Shares Change (YoY) | +0.07% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 34.88% |
| Owned by Institutions (%) | 14.87% |
| Float | 19.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.53 |
| P/TBV Ratio | 0.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 29.15
| Current Ratio | 29.15 |
| Quick Ratio | 28.93 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -64.99 |
Financial Efficiency
Return on equity (ROE) is -20.53% and return on invested capital (ROIC) is -14.33%.
| Return on Equity (ROE) | -20.53% |
| Return on Assets (ROA) | -13.78% |
| Return on Invested Capital (ROIC) | -14.33% |
| Return on Capital Employed (ROCE) | -25.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$428,402 |
| Employee Count | 92 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -28,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -64.61% in the last 52 weeks. The beta is 0.97, so XBiotech's price volatility has been similar to the market average.
| Beta (5Y) | 0.97 |
| 52-Week Price Change | -64.61% |
| 50-Day Moving Average | 3.10 |
| 200-Day Moving Average | 5.14 |
| Relative Strength Index (RSI) | 52.52 |
| Average Volume (20 Days) | 60,024 |
Short Selling Information
The latest short interest is 898,575, so 2.95% of the outstanding shares have been sold short.
| Short Interest | 898,575 |
| Short Previous Month | 697,589 |
| Short % of Shares Out | 2.95% |
| Short % of Float | 4.53% |
| Short Ratio (days to cover) | 14.26 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -45.17M |
| Pretax Income | -30.44M |
| Net Income | -39.41M |
| EBITDA | -43.41M |
| EBIT | -45.17M |
| Earnings Per Share (EPS) | -$1.29 |
Full Income StatementBalance Sheet
The company has $155.90 million in cash and n/a in debt, giving a net cash position of $155.90 million or $5.11 per share.
| Cash & Cash Equivalents | 155.90M |
| Total Debt | n/a |
| Net Cash | 155.90M |
| Net Cash Per Share | $5.11 |
| Equity (Book Value) | 174.71M |
| Book Value Per Share | 5.73 |
| Working Capital | 152.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$30.48 million and capital expenditures -$1.14 million, giving a free cash flow of -$32.27 million.
| Operating Cash Flow | -30.48M |
| Capital Expenditures | -1.14M |
| Free Cash Flow | -32.27M |
| FCF Per Share | -$1.06 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |